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C l i n i c a l  r e s e a r c h
Tobacco use disorder and treatment: new 
challenges and opportunities
Douglas Ziedonis, MD, MPH; Smita Das, MD, PhD, MPH; 
Celine Larkin, PhD
Tobacco use remains a global problem, and options for consumers have increased with the development and mar-
keting of e-cigarettes and other new nicotine and tobacco products, such as “heat-not-burn” tobacco and dissolv-
able tobacco. The increased access to these new products is juxtaposed with expanding public health and clinical 
intervention options, including mobile technologies and social media. The persistent high rate of tobacco-use dis-
orders among those with psychiatric disorders has gathered increased global attention, including successful ap-
proaches to individual treatment and organizational-level interventions. Best outcomes occur when medications 
are integrated with behavioral therapies and community-based interventions. Addressing tobacco in mental health 
settings requires training and technical assistance to remove old cultural barriers that restricted interventions. There 
is still “low-hanging fruit” to be gained in educating on the proper use of nicotine replacement medications, how 
smoking cessation can change blood levels of specific medications and caffeine, and how to connect with quitlines 
and mobile technology options. Future innovations are likely to be related to pharmacogenomics and new tech-
nologies that are human-, home-, and community-facing.      
© 2017, AICH – Servier Research Group  Dialogues Clin Neurosci. 2017;19:271-280.
Introduction
 Tobacco use is the cause of over 5 million deaths 
per year globally,1 over twice as many deaths due to al-
cohol and illicit drugs combined. If current consump-
tion rates continue, tobacco is projected to kill 1 billion 
people this century, with the majority of deaths occur-
ring in low- and middle-income countries,2 although 
there is good evidence for the effectiveness both of pol-
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icies2 and pharmacological interventions3 in developing 
countries. An important subgroup of smokers that con-
tinues to use tobacco at a high rate includes those with 
mental illness or other addictions. A recent publication 
by the Royal College of Physicians (2013) provides an 
excellent summary of this previously neglected and 
overlooked population of tobacco users. Tobacco-use 
disorders are usually not isolated Diagnostic and Statis-
tical Manual of Mental Disorders (DSM) diagnoses. To-
bacco use is two to three times more prevalent among 
patients with other psychiatric disorders, including 
anxiety, attention-deficit, mood, and other substance-
use disorders. Forty-four percent of all cigarettes in the 
United States are consumed by smokers with mental ill-
ness,4 and in mental health and addiction treatment set-
tings, 50% to 95% are smokers.5 Unfortunately, smok-
ing rates in this vulnerable population remain high 
despite the general trend for decreasing smoking rates 
in the United States as a whole. 
 This article will focus on important new issues in the 
assessment and treatment of tobacco-use disorders, in-
cluding those with comorbid psychiatric disorders; new 
emerging tobacco and nicotine products, mobile tech-
nologies, and social media interventions; and future pos-
sibilities for pharmacogenomics and integrating tech-
nologies. Nicotine-receptor pharmacology and genetic 
variations have been a fruitful area in understanding 
the fundamental neuroscience of tobacco-use disorders, 
and they open windows to tailoring treatment based on 
genetic subtypes of fast/slow metabolism of nicotine 
and by specific pharmacotherapy agents. Assessment of 
nicotine and tobacco now must consider new delivery 
devices beyond cigarettes, including e-cigarettes, heat-
not-burn delivery systems, and global products of other 
nicotine- and tobacco-related products.
 Nicotine is a naturally occurring pesticide found on 
tobacco leaves and is the addictive substance in tobacco 
or cigarette smoke. When nicotine or tobacco is admin-
istered orally (nicotine-replacement therapy [NRT] 
medication, dissolvable tobacco, tobacco chew, snuff, 
etc), absorption is slow and takes 10 to 15 minutes. 
When nicotine is inhaled as smoke, it quickly reaches 
the alveoli of the lungs, and within 11 seconds of a puff, 
reaches the brain through the blood stream and cross-
ing the blood-brain barrier. Nicotine then binds to nico-
tinic acetylcholine receptors (nAChRs) found through-
out the brain. nAChRs have several α and β subunits, 
arranged in a pentamer configuration. One of the most 
common subtypes is α4β2 (which has two or three α4 
units and three or two β2 units) and has a high affinity 
for nicotine. Animal models and pharmacologic agents 
have identified the α4 and β2 subunits of the nicotine 
receptor as contributing to nicotine-reinforcing ef-
fects.6,7 These ligand-gated receptors open with nicotine 
or acetylcholine and allow for the flow of ions.8 
 Nicotine arrives more quickly, and exhibits higher 
brain peaks, with cigarettes and e-cigarettes than other 
tobacco products, such as water pipes, dissolved nico-
tine, or the wide range of NRT products (oral gum, 
lozenge, inhaler, nasal spray, dermal patch). Smokers 
can also modulate their nicotine intake through the 
amount they smoke and how they smoke, for example, 
how deeply they inhale and whether they cover venting 
holes on cigarettes.9 In dependent smokers, repeated 
exposure to nicotine peaks can desensitize nAChRs 
so that they are less responsive, requiring a smoker to 
smoke more.10 In contrast, nicotine replacement patch-
es release a stable amount of nicotine in the blood, 
eliminating peaks and alleviating dependence. 
 A newer version of diagnostic criteria was released 
in 2013 with the DSM-5,11 the fifth edition of the DSM, 
which now classifies “tobacco addiction” or “nicotine 
dependence” as a “tobacco-use disorder,” similar to 
other substances. Diagnostic criteria for substance-use 
disorder require that at least two of 11 conditions listed 
(such as using more than intended, unsuccessful effort 
to cut down, time spent using, failure to fulfill life obliga-
tions, or giving up activities and use despite knowledge 
of the consequences) occur within a 12-month period. 
The DSM-511 criteria for tobacco-use disorder continue 
the tradition of blending the dependence syndrome12 
and biological symptoms of tolerance and withdrawal 
while adding a new diagnostic criterion of craving. The 
latter addition illustrates the growing acceptance that 
craving is a central component in substance use,13 de-
spite a systematic review suggesting that craving is a 
poor predictor of relapse.14
Alternative modes of nicotine delivery
Cigarette smoking is the most prevalent form of nico-
tine delivery. However, alternative modes are becom-
ing more common, including e-cigarettes and heat-
not-burn and dissolvable-tobacco delivery systems. 
Between 2010 and 2013, lifetime use of e-cigarettes 
among US adults increased significantly from 3.3% to 
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8.5%.15 Rates of lifetime use are even higher in cur-
rent cigarette smokers, 36.5% in 2013, whereas only 
1.3% of nonsmokers report having tried e-cigarettes. 
Sixty percent of current smokers report lifetime use of 
e-cigarettes, and half report regular use.16 Even though 
e-cigarettes were initially promoted as a safer alterna-
tive to cigarettes, they are still a direct method of nico-
tine exposure. Compared with traditional cigarettes, 
nicotine exposure varies based on experience level of 
the user, whereby nicotine and cotinine are less concen-
trated for inexperienced users.17 A cigarette has about 6 
to 11 mg of nicotine, resulting in 1 to 2 mg absorbed per 
cigarette.18 Cigars can contain 100 to 444 mg of nicotine, 
resulting in 9 to 68 mg absorbed. A nicotine cartridge 
for an electronic nicotine delivery system has 6 to 24 mg 
per mL of nicotine, and a whole cartridge can yield 2.5 
to 7.7 mg inhaled nicotine.19 Contemporary electronic 
cigarettes have been shown to match or even exceed 
the nicotine delivery of a regular cigarette. 
 Nicotine causes release of dopamine and upregula-
tion of receptors, resulting over time in nicotine depen-
dence and craving with the drive to return to consuming 
nicotine. Table I summarizes the main effects of the oth-
er neurotransmitters that are released by nicotine bind-
ing.18 Nicotine’s short half-life of 1 to 2 hours leads to 
withdrawal symptoms of irritability, frustration, anxiety, 
difficulty concentrating, restlessness, depressed mood, 
insomnia, increased appetite, weight gain, and cravings.
 While e-cigarette cartridges have 6 to 24 mg of nico-
tine per mL, a study of 32 of the most popularly manu-
factured e-cigarette products in the US-made cartridges 
found trace nicotine in three products labeled as nicotine 
free and found that nine products showed differences 
between labeled and detected nicotine concentrations 
larger than 20%.20 In the European Union, regulations 
have recently been introduced to improve the accuracy 
of labeling of e-cigarettes. A recent study showed that 
next-generation e-cigarettes may even exceed the nico-
tine delivery of a regular cigarette.21 Another concern 
that may make these devices more addictive is the fla-
vored options, which can appeal to youth, who are more 
vulnerable to addiction. Past-month e-cigarette use near-
ly tripled from 2013 to 2014 among high school students 
(4.5% to 13.4%), surpassing all other tobacco use.22 An 
ongoing study of these newer products confers an over 
four times greater risk of cigarette smoking 1 year later 
in adolescents.23 Heat-not-burn products are a very re-
cent addition to the smokeless tobacco market, though 
not yet available in the United States. Initial evidence 
suggests that smoke from these products, which were de-
veloped by tobacco companies, still contains volatile or-
ganic compounds, polycyclic aromatic hydrocarbons, and 
carbon monoxide, as well as 84% of the nicotine found in 
conventional cigarette smoke.24 Recent research shows 
that e-cigarette dual use is of concern in current smok-
ers and is not a definitive method of quitting. A recent 
systematic review and meta-analysis found that in three 
cohort studies, there was no evidence that nicotine or 
non-nicotine electronic delivery systems helped people 
quit smoking.25 In a meta-analysis of clinical trials and 
observational real-world studies, 20 controlled stud-
ies were analyzed,26 and the odds of quitting cigarettes 
were 28% lower in those who used e-cigarettes than in 
those who did not use e-cigarettes, regardless of whether 
or not smokers were interested in quitting. In contrast, 
a systematic review from 201527 identified only six stud-
ies and reported that nicotine-filled e-cigarettes were 
more effective for cessation than those without nicotine. 
Similarly, a systematic review published last year28 identi-
fied 62 studies of mostly lower quality and reported that 
e-cigarettes may be helpful for some smokers in smok-
ing cessation or reduction. Taken as a whole, research to 
date does not support use of e-cigarettes for cessation; 
there is a need for more research on this topic. E-ciga-
rettes can trigger use of traditional cigarettes.29 Finally, 
although e-cigarettes may potentially reduce harm from 
the combustible products of traditional cigarettes, there 
is still not enough known about the byproducts and ef-
fects of e-cigarettes. Access and ingestion of nicotine in 
high doses, especially for nonsmokers and children, can 
be dangerous and even fatal.
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Neurotransmitter Effect
Dopamine Pleasure, appetite suppression
Norepinephrine Arousal, appetite suppression
Acetylcholine Arousal, cognitive enhancement
Glutamate Learning, memory enhancement
Serotonin Mood modulation, appetite suppression
β-Endorphin Reduction in anxiety and tension
GABA Reduction in anxiety and tension
Table I.  Main effects of neurotransmitters that are released by nico-
tine binding. GABA, γ-aminobutyric acid
  Adapted from reference 18: Benowitz. Clinical pharmacology of nico-
tine: implications for understanding, preventing, and treating tobacco 
addiction. Clin Pharmacol Ther. 2008;83(4):531-541.
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Treatment of tobacco-use disorder/
nicotine dependence
There are seven evidence-based US Food and Drug 
Administration (FDA)-approved pharmacotherapies 
for tobacco-use disorder, as well as several evidence-
based psychosocial interventions with the need for fur-
ther study of emerging new options of person-, home-, 
and community-facing technologies (Table II).30-38 With 
the highest rates of tobacco-use disorders among peo-
ple with psychiatric disorders, there is a need to con-
tinue to consider adapted and innovative treatments for 
this subgroup of users, especially given the increased as-
sociated morbidity and mortality, including the shorter 
life span—by as much as 25 years—among those with 
serious mental illness.5 
Medication options
There are seven FDA-approved medications for smok-
ing cessation, including two non-nicotine replacement 
pill options of bupropion (Zyban) and varenicline 
(Chantix) and five nicotine-replacement therapies 
(NRTs). NRT patches, gum, and lozenges are available 
over-the-counter, whereas, in the United States, NRT 
inhaler and nasal spray are available by prescription 
only. Varenicline (Chantix) appears to be the most ef-
fective compared with placebo, followed by bupropi-
274
Intervention Details Appraisal Setting Key  
references
Integrated/ 
combined treat-
ment
Examples
-  Using a combined psychosocial and 
pharmacological approach
-  Treating tobacco-use disorder concur-
rently with other illnesses and psychiat-
ric disorders
-  Concurrently pairing a long-acting NRT 
(ie, nicotine patch) with a short-acting 
NRT (ie, gum, lozenge, inhaler, or nasal 
spray)
-  Concurrently pairing a long-acting 
medication, such as varenicline or bu-
propion, with a rescue medication, such 
as the gum or lozenge
-  Integrated treatment delivers the 
best outcomes
-  Medications can complement each 
other, and combined psychosocial 
and pharmacological approaches 
can address both psychological and 
biological dependence 
Clinical Lancaster et 
al,30 2000
Stead et 
al,31 2015
Stead et 
al,32 2016
Constituent treatments
Nicotine re-
placement ther-
apies (NRT)
Five types: patch, gum, lozenge, inhaler, 
and nasal spray 
- FDA-approved 
- Relatively low cost
-  Marginally less effective than Var-
enicline and Bupropion 
-  Offer more steady delivery of nico-
tine than cigarettes, reducing rein-
forcement
-  Patch, gum, lozenge over-the-
counter 
-  Inhaler and nasal spray by prescrip-
tion only in the United States
Clinical; 
nonclinical
Lawrence et 
al,33 2009
Varenicline 
(Chantix)
Relieves craving and withdrawal, reduc-
ing the reinforcing effects of nicotine
-  Most effective of the pharmacologi-
cal interventions
- FDA-approved
-  Be aware of black-box warning for 
cardiovascular adverse events
-  Be aware of possible neuropsychiat-
ric symptoms in some patients (de-
pressed mood, agitation, suicidality) 
Clinical Lawrence et 
al,33 2009
Table II.  Recommended treatment for nicotine dependence. CBT, cognitive behavior therapy; FDA, US Food and Drug Administration; MAOI, 
Monoamine oxidase inhibitors; NicA, Nicotine Anonymous; NRT, nicotine replacement therapy; SR, sustained release
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on and NRTs.39 Varenicline is a partial agonist at the 
α4β2 neuronal nAChR; as a partial agonist, it relieves 
craving and withdrawal, but reduces the reinforcing ef-
fects of nicotine by blocking dopaminergic stimulation 
(less smoking reinforcement/reward). Bupropion (Zy-
ban) is the other medication that can affect dopamine, 
norepinephrine, and nicotinic-cholinergic receptors to 
decrease cravings and withdrawal symptoms. NRTs 
function to satisfy nicotine receptors while being less 
reinforcing. Whereas plasma nicotine sharply peaks 
within 5 minutes of cigarette use, NRTs offer a more 
steady delivery of nicotine, thereby satisfying but not 
reinforcing. In addition to having slower delivery, NRT 
only offers 30% to 75% of the amount of nicotine that 
would be acquired from smoking. To achieve substitu-
tion, the NRT should roughly match the individual’s 
pretreatment level of nicotine. Many factors influence 
what amount of nicotine replacement might be needed 
to reduce or eliminate craving for nicotine, including 
the range of smoking behaviors, which effect levels of 
nicotine consumed from a cigarette (individuals can 
have longer or shorter inhalation breaths and longer or 
shorter time periods between puffs); external environ-
mental triggers (living with a smoker or working with 
smokers, etc); and genetic variation on the metabolism 
of nicotine (faster/slower metabolism). 
 Choice of medication depends on history, patient in-
put, cost, previous attempts, and severity of dependence/
withdrawal and breakthrough symptoms. Although cost 
effectiveness has yet to be verified,40 these therapies can 
be effectively used in combination, for example, by con-
currently pairing a long-acting NRT (ie, nicotine patch) 
with a short-acting NRT (ie, gum, lozenge, inhaler, or 
nasal spray) or combining a long-acting medication, 
such as varenicline or bupropion, with a rescue medica-
tion, such as the gum or lozenge.30 
 Whereas smoking exposure during pregnancy is well 
recognized as a risk factor for premature birth, growth 
retardation and adverse long-term neurobehavioral ef-
fects, the effects of prenatal exposure to nicotine are 
less well known. We do know that nicotine is metabo-
lized more quickly in pregnant women, easily passes the 
placental barrier, and accumulates in breast milk. More-
over, there is emerging evidence that prenatal nicotine 
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Bupropion SR 
(Zyban)
An antidepressant that reduces cravings 
and other withdrawal effects
- Effective, but less so than Varenicline
- FDA-approved
-  Do not use with seizure disorders, 
current use of bupropion, or MAOIs, 
electrolyte abnormalities, eating 
disorders
Clinical Lawrence et 
al,33 2009
Individual psy-
chological inter-
vention
Examples include brief counseling, moti-
vational interviewing, cognitive behavior 
therapy
-  Addresses psychological motivation 
to use tobacco and to quit
-  Even brief interventions have been 
shown to be effective 
Clinical Stead et 
al,34 2013
Lindson-
Hawley et 
al,35 2015
Group support NicA, online support groups, CBT-based 
groups
-  Leverages social support and social 
modeling in quitting
-  Aligns with other peer-support mod-
els for substance dependence
-  More effective than self-help, but 
not more effective than individual 
counseling
Communi-
ty, clinical, 
online
Steadt et 
al,36 2005
Mobile tech-
nologies
Text-message support, limited number of 
mobile apps
-  Limited evidence for publicly avail-
able apps
-  Text-messaging support has been 
shown to be effective
Communi-
ty, online
Free et al,37 
2011
Abroms et 
al,38 2013
Organizational 
interventions
Smoke-free institutions, workplace coun-
seling
-  Provides environmental supports for 
quit attempts, reducing cues and 
increasing motivation
-  Effective when combined with indi-
vidual interventions
Commu-
nity
Abroms et 
al,38 2013
Table II.  Continued
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exposure is associated with premature birth, stillbirth, 
and abnormal brain development.41,42 
Patient education
Clinicians have an opportunity to greatly impact treat-
ment outcomes by enhancing patient education on 
key issues. Often, nicotine replacement products are 
used incorrectly, particularly the “chewing” of nicotine 
gum as opposed to the recommended “bite and park” 
technique. Patients are often not told that blood levels 
of caffeine and many specific medications rise when 
someone quits smoking; thus, patients may experience 
symptoms of caffeine intoxication (doubling of caffeine 
levels in the blood with no change in caffeine intake43) 
or side effects from specific medications (such as seda-
tion, rigidity, etc, from specific antipsychotics and other 
medications). These interactions are a result of tobacco-
smoke–metabolism interactions and not nicotine itself. 
The clinical encounter is an opportunity to educate pa-
tients on the appropriate way to take medications and 
also how to access quitlines available in the state, Nico-
tine Anonymous phone meetings, and Internet sites 
and mobile technology options, including texting and 
numerous apps. 
 There is strong evidence that combining psychosocial 
and pharmacological approaches is most effective.31,32 
Important psychosocial or community-based interven-
tions can be used without medications, including indi-
vidual and group counseling with behavioral therapy, 
phone counseling (quitlines), and text messaging inter-
ventions. Individual interventions, such as brief counsel-
ing and motivational interviewing in health settings, are 
particularly effective,34,35 although a systematic review of 
patients hospitalized for coronary heart disease showed 
they required a longer duration of engagement.44 
Adjusting for psychiatric comorbidity
Treatment approaches may need to be adjusted slightly 
when addressing tobacco-use disorders among indi-
viduals with co-occurring psychiatric disorders; these 
individuals have disproportionately high rates of to-
bacco use. Those living with serious mental illness have 
a life expectancy that is 25 years lower than the general 
population,45 a difference largely due to tobacco use as 
well as obesity and poor engagement in medical care.46-48 
Those experiencing mental illness are about twice as 
likely to be a smoker as the general population4,33 and 
have lower rates of quitting.4 Moreover, smoking tobac-
co can affect the metabolism of certain antidepressant 
and antipsychotic medications, particularly accelerating 
those primarily metabolized by cytochrome P450 1A2 
(CYP1A2). Inequalities in tobacco-related mortality 
and morbidity are mutable with changes in clinician be-
havior to engage these individuals through willingness 
to engage, provision of treatment planning, and multiple 
treatment efforts. Nicotine may function, in the short 
term, to reduce certain psychiatric symptoms; however, 
there are no long-term benefits to ongoing tobacco use, 
and there are clear benefits from quitting. Individuals 
with schizophrenia may exhibit impaired sensory gating 
(related to polymorphisms on the α7 nicotinic recep-
tor gene on the chromosome 15q14 locus), which can 
improve temporarily after nicotine use.49 On the other 
hand, smoking cessation leads to significant reductions 
in anxiety, depression, and stress in both psychiatric and 
nonpsychiatric populations.50 
 There is a growing literature on treatment options 
for tobacco users with comorbid psychiatric disorders, 
and there is consensus that clinical care of those with 
serious mental illness should include tobacco cessation 
and implementation of evidence-based interventions 
for smoking cessation. Earlier fears of chaos and de-
terioration after smoking cessation in this group have 
proven unfounded. Studies show comparable51 or im-
proved50 mood and quality of life among quitters, with 
few adverse individual or treatment program organi-
zational effects.46 Common smoking cessation treat-
ments, such as bupropion and varenicline, have been 
shown to be well tolerated and effective in those with 
serious mental illness.51,52 Psychosocial strategies, such 
as pragmatic goal-setting and self-monitoring, may 
be particularly helpful adjuncts for individuals whose 
mental illness is associated with lower motivation and 
self-efficacy. “Learning about Healthy Living” is an ex-
ample of a psychoeducational program for psychiatric 
patients, addressing how tobacco use enhances recov-
ery and wellness.53 Other interventions for smoking 
cessation leverage social support, which appears to be 
particularly helpful for men.54,55 
Use of mobile technology
There is increasing interest in the potential of mobile 
technologies in aiding smokers to quit. Programs range 
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from simple text messaging to applications that allow 
for interactive progress tracking. A Cochrane review56 
showed that mobile phone interventions significantly 
increase the long-term quit rates compared with con-
trol programs. Most of the existing evidence-based in-
terventions in this area use text messaging, for example, 
the “txt2stop” intervention.37 At comparatively low 
cost, mobile applications have the potential to bolster 
self-management with instantaneous measurement and 
feedback; but at present, it is too early to endorse any 
mobile applications as being truly evidence based. The 
quality of publicly available mobile applications is low, 
as few of these have been tested or even have adequate 
face validity. One study located a total of 252 smoking-
cessation apps for iPhone and 148 for Android, report-
ing that popular apps scored low on adherence to the 
US Public Health Service’s Clinical Practice Guidelines 
for Treating Tobacco Use and Dependence.38 Very few 
publicly available apps recommended medications, and 
no apps recommended calling a quitline, despite the ef-
fectiveness of these services. Although there is much 
potential in this area, there is still a need for further re-
search on this rapidly growing technology option that 
now is including home- and community-facing technol-
ogy through carbon-monoxide meters and real-time 
changes in measurements. There is a need for evidence-
based mobile applications for smoking cessation to be 
more readily available. 
Organizational-level approaches
New tobacco products and the potential for “person-
alized medicine” imply that potential changes must be 
part of the treatment culture to increase awareness and 
the willingness to integrate new treatments. Fundamen-
tally, each treatment agency has a culture that supports 
addressing tobacco or not. Since tobacco-use–disorder 
treatment is often not reimbursed, there is often no in-
centive to treat, and indeed, there are disincentives per-
taining to clinician time and agency resources. Histori-
cally, mental health and addiction treatment programs 
have been lenient and even supportive of tobacco use 
by their clients and staff. There is a need to improve 
staff training, to help staff quit smoking, to provide a 
tobacco-free campus, and to offer services including 
patient education on medications, side effects, changes 
in blood levels of caffeine and medication, and on how 
to engage in psychosocial and community-based op-
tions, such as quitlines, mobile technology, and Nico-
tine Anonymous. Having carbon-monoxide meters as 
standard equipment supports assessment and manage-
ment. Rxforchange.ucsf.edu, for example, is a free and 
evidence-based training resource online with a curricu-
lum specifically for psychiatric providers who want to 
change culture and treat tobacco use. There are also 
curricula on the website for other types of providers, 
including those in cardiology, respiratory care, and gen-
eral medicine.
 Organizational-change interventions, such as the 
Addressing Tobacco Through Organizational Change 
(ATTOC) model, have been used to help many men-
tal health and addiction treatment programs in chang-
ing clinicians’ attitudes and organizational readiness 
to address tobacco; however, more research is needed. 
Having agency leadership support, local champions, 
work-group teams, enhanced communication, trainings, 
practical changes to support more interventions, and 
monitoring of changes in both organizational processes 
and individual client outcomes is feasible and can lead 
to changes in staff attitudes, skills, and services provided 
at these agencies.57
Emerging medications
There are seven FDA-approved medications, which are 
discussed above, and emerging science may result in ad-
ditional options in the future. For example, cytisine is 
a naturally occurring plant alkaloid, like nicotine, and 
functions similarly to varenicline, with strong binding 
affinity for the nAChR. It is considered first-line thera-
py in many Eastern European countries. Other targets 
may inhibit cytochrome P450 2A6 (CYP2A6), which 
is the major metabolizer of nicotine. Medications that 
are used for opiate-use disorder may reduce nicotine 
intake, suggesting that opioid receptors modulate the 
reinforcing effects of nicotine.58 Two other medications 
of interest are mecamylamine, a noncompetitive antag-
onist of nicotinic cholinergic receptors and lobeline, an 
alkaloid and nicotine receptor agonist. These medica-
tions work in different ways with the former blocking 
nicotine effects, as well as reinforcement, and the latter 
satisfying the nicotine receptor. Currently, phase 1 and 
phase 2 clinical trials are looking at nicotine vaccines, 
which produce antibodies that can bind to nicotine to 
prevent nicotine from acting on receptors,59 with limit-
ed effects. Research is relatively recent, and a potential 
C l i n i c a l  r e s e a r c h
concern is that with such a vaccine users might increase 
their intake of nicotine to overcome the effects of the 
vaccine.
Pharmacogenomics and tobacco-use 
disorders: insights that may lead to new 
treatments
Genome-wide association studies are now identifying 
single nucleotide polymorphisms on specific genes that 
are implicated in tobacco-use disorders. CHRNA5 (cho-
linergic receptor nicotinic α5 subunit) was the first gene 
of interest in 2007,60 and shortly thereafter, CHRNA3 
(cholinergic receptor nicotinic α3 subunit) was identi-
fied.61 The CHRNA5–CHRNA3–CHRNB4 gene clus-
ter on chromosome 15 encodes for most of the α- and 
β-receptor subunits of interest in nicotine dependence, 
and changes in specific amino acids of these genes lead 
to varying levels of nicotine agonist response.62 In hu-
man studies, homozygosity for a CHRNA5 major allele 
is associated with reduced volume of smoke inhaled 
per puff when the nicotine content of a cigarette is in-
creased.63 Also, variants of the CHRNA5–CHRNA3–
CHRNB4 gene cluster are associated with cotinine 
levels in smokers.64 CHRNB2 (encodes the β2 subunit) 
are important for the β2 nAChR subunit function, 
which can be protective against the initiation of regular 
smoking by decreasing dopamine release during early 
smoking experiences.6 This is relevant because roughly 
one-third of people who try smoking go on to become 
dependent. Targeting specific receptor subunits, most 
involved in addiction, may help with medication devel-
opment in the future. 
 In addition to susceptibility to nicotine and nicotine 
dependence, genetic studies also can inform responsiv-
ity to the currently FDA-approved medication treat-
ments. For example, CHRNA5 markers may indicate 
response to nicotine replacement therapy.65 Such in-
sights could lead to precision-medicine targets; how-
ever, medications such as NRT are underutilized, and 
increasing access and use of these medications, regard-
less of allele, is also imperative. 
 Nicotine clearance is also important for mediat-
ing nicotine’s effects and is mostly metabolized in the 
liver; individual variation in liver metabolism leads to 
different smoking behaviors.66 Most nicotine is cleared 
through CYP2A6 metabolism, converting nicotine into 
cotinine and then to trans-3’-hydroxycotinine (3HC). 
Both metabolites are detectible in the urine; general-
ly, cotinine is a biomarker for nicotine exposure, with 
a long half-life of about 16 hours.67 Different rates of 
CYP2A6 (loss of alleles *2 and *4) metabolism can be 
associated with varying degrees of addiction risk, quit 
rates, and medication efficacies.68,69
Conclusion
Tobacco use continues to increase morbidity and mor-
tality with high rates of tobacco-use disorders among 
individuals with psychiatric disorders resulting in se-
vere health disparities for that population. New nicotine 
and tobacco products will continue to be developed, as 
will new treatments, with increasing person-, home-, 
and community-facing technologies. The dialogue must 
include how to effectively implement the existing evi-
dence-based resources that are available, which will re-
quire more training, support tools, technical assistance 
at the organizational level, and a hopeful attitude. 
 Reducing tobacco use in the broader population re-
quires a multipronged approach. In terms of prevention, 
initiating use of emerging nicotine delivery systems, 
such as e-cigarettes, should continue to be discouraged, 
with early interventions among children and adoles-
cents. Treatment of tobacco-use disorder is optimized 
by the integration of evidence-based pharmacological 
and psychosocial treatments, as well as effective imple-
mentation in real-world settings. Special attention must 
be paid to organizations treating individuals with men-
tal illness and substance-use disorders because of the 
long traditions of ignoring tobacco use and the persis-
tent clinical indifference to the disease burden caused 
by tobacco use in these populations. Our knowledge of 
the effects and effective treatments of nicotine use has 
increased rapidly in the last decades, but there is much 
yet to do. o
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El trastorno por uso de tabaco y su tratamiento: 
nuevos desafíos y nuevas oportunidades 
El uso de tabaco sigue siendo un problema mundial, y 
las opciones para los consumidores han aumentado con 
el desarrollo y comercialización de cigarrillos electróni-
cos y otros nuevos productos de la nicotina y del taba-
co, como el tabaco que “calienta pero no quema” y el 
tabaco soluble. El aumento del acceso a estos nuevos 
productos está yuxtapuesto con el desarrollo de la salud 
pública y de las opciones de intervenciones clínicas, in-
cluyendo las tecnologías móviles y los medios de comu-
nicación social. El persistente aumento en la frecuencia 
de los trastornos por uso de tabaco entre los pacientes 
con trastornos psiquiátricos ha atraído una mayor aten-
ción mundial, incluyendo intervenciones exitosas a nivel 
de los tratamientos individuales y en las organizaciones. 
Los mejores resultados se obtienen cuando se combi-
nan medicamentos con terapias conductuales e inter-
venciones a nivel de la comunidad. El tratamiento del 
tabaquismo en los ambientes de salud mental requie-
re entrenamiento y asistencia técnica para remover las 
antiguas barreras culturales que restringen las interven-
ciones. Todavía hay posibilidades fáciles para enseñar la 
utilización correcta de medicamentos que reemplacen 
a la nicotina, para saber que el dejar de fumar puede 
modificar los niveles plasmáticos de determinados fár-
macos y de cafeína, y para conocer cómo conectarse con 
aplicaciones de tecnologías móviles y líneas telefónicas 
orientadas a dejar de fumar. Es probable que las futuras 
innovaciones estén relacionadas con la farmacogenómi-
ca y con nuevas tecnologías orientadas a los humanos, a 
la casa y a la comunidad.      
Nouveaux défis et nouvelles opportunités du 
traitement et des troubles de l’usage du tabac
L’usage du tabac reste un problème mondial, de nou-
velles options se présentant aux consommateurs avec le 
développement et la commercialisation des cigarettes 
électroniques et d’autres nouveaux produits dérivés du 
tabac et de la nicotine, comme le tabac « qui chauffe 
mais ne brûle pas » et le tabac soluble. L’accès accru à ces 
nouveaux produits se juxtapose au développement de 
la santé publique et aux options d’intervention clinique, 
telles que les technologies mobiles et les médias sociaux. 
L’attention générale s’est focalisée sur le taux élevé per-
sistant des troubles liés au tabac parmi les patients qui 
ont des troubles psychiatriques, et notamment sur le 
succès des traitements individuels et des interventions 
organisationnelles. Les résultats sont meilleurs quand 
les traitements sont intégrés à des thérapies comporte-
mentales et à des interventions de proximité. Le traite-
ment du tabagisme dans le cadre de la santé mentale 
nécessite une formation et une assistance technique 
pour supprimer les barrières culturelles qui restreignent 
les interventions. Il existe encore des solutions faciles à 
mettre en œuvre pour éduquer les patients à l’utilisa-
tion correcte des substituts nicotiniques, leur expliquer 
comment l’arrêt du tabac change les taux sanguins de 
certains médicaments spécifiques et de la caféine et leur 
apprendre à se connecter aux applications mobiles et 
aux lignes téléphoniques dédiées à l’arrêt du tabac. De 
futures innovations seront probablement liées à la phar-
macogénomique et à de nouvelles technologies qui se-
ront tournées vers l’humain, la maison et la population. 
